Table 4.
The clinical characteristics of combined hepatocellular carcinoma and cholangiocarcinoma patients undergoing specific surgical strategies.
| Variables | Liver transplant | Ref | Wedge resection | P value | Lobectomy | P value |
|---|---|---|---|---|---|---|
| All patients | 38 | 52 | 51 | |||
| Year of diagnosis | Ref | 0.01 | 0.26 | |||
| 2004-2009 | 21 (55.3%) | 14 (26.9%) | 22 (43.1%) | |||
| 2010-2015 | 17 (44.7%) | 38 (73.1%) | 29 (56.9%) | |||
| Gender | Ref | 0.16 | 0.20 | |||
| Male | 30 (78.9%) | 34 (65.4%) | 34 (66.7%) | |||
| Female | 8 (21.1%) | 18 (34.6%) | 17 (33.3%) | |||
| Ethnicity | Ref | 0.22 | 0.15 | |||
| Caucasian | 30 (78.9%) | 36 (69.2%) | 33 (64.7%) | |||
| African–American | 5 (13.2%) | 5 (9.6%) | 6 (11.8%) | |||
| Others | 3 (7.9%) | 11 (21.2%) | 12 (23.5%) | |||
| Age at diagnosis | Ref | 0.05 | 0.06 | |||
| ≤60 | 24 (63.2%) | 22 (42.3%) | 22 (43.1%) | |||
| >60 | 14 (36.8%) | 30 (57.7%) | 29 (56.9%) | |||
| Marital status | Ref | 0.12 | 0.23 | |||
| Married | 23 (60.5%) | 35 (67.3%) | 30 (58.8%) | |||
| Single | 11 (28.9%) | 7 (13.5%) | 9 (17.6%) | |||
| Divorced/separated | 1 (2.6%) | 7 (13.5%) | 7 (13.7%) | |||
| Widowed | 3 (7.9%) | 3 (5.8%) | 5 (9.8%) | |||
| Tumor size | Ref | 0.13 | 0.07 | |||
| ≤ 5 cm | 23 (60.5%) | 23 (44.2%) | 21 (41.2%) | |||
| > 5 cm | 15 (39.5%) | 29 (55.8%) | 30 (58.8%) | |||
| Grade | Ref | 0.19 | 0.01 | |||
| I | 3 (7.9%) | 4 (7.7%) | 0 (0.0%) | |||
| II | 17 (44.7%) | 15 (28.8%) | 15 (29.4%) | |||
| III | 18 (47.4%) | 29 (55.8%) | 29 (56.9%) | |||
| IV | 0 (0.0%) | 4 (7.7%) | 7 (13.7%) | |||
| TNM stage | Ref | 0.47 | 0.58 | |||
| I | 13 (34.2%) | 17 (32.7%) | 13 (25.5%) | |||
| II | 13 (34.2%) | 10 (19.2%) | 14 (27.5%) | |||
| III | 6 (15.8%) | 13 (25.0%) | 15 (29.4%) | |||
| IV | 4 (10.5%) | 9 (17.3%) | 7 (13.7%) | |||
| Unknown stage | 2 (5.3%) | 3 (5.8%) | 2 (3.9%) | |||
| T stage | Ref | 0.30 | 0.22 | |||
| T1 | 15 (39.5%) | 20 (38.5%) | 15 (29.4%) | |||
| T2 | 15 (39.5%) | 12 (23.1%) | 18 (35.3%) | |||
| T3 | 5 (13.2%) | 11 (21.2%) | 16 (31.4%) | |||
| T4 | 3 (7.9%) | 7 (13.5%) | 2 (3.9%) | |||
| TX | 0 (0.0%) | 2 (3.8%) | 0 (0.0%) | |||
| N stage | Ref | 0.69 | 0.20 | |||
| N0 | 31 (81.6%) | 39 (75.0%) | 44 (86.3%) | |||
| N1 | 6 (15.8%) | 10 (19.2%) | 3 (5.9%) | |||
| NX | 1 (2.6%) | 3 (5.8%) | 4 (7.8%) | |||
| M stage | Ref | 0.65 | 0.87 | |||
| M0 | 32 (84.2%) | 40 (76.9%) | 42 (82.4%) | |||
| M1 | 4 (10.5%) | 9 (17.3%) | 7 (13.7%) | |||
| MX | 2 (5.3%) | 3 (5.8%) | 2 (3.9%) | |||
| Chemotherapy | Ref | 0.07 | 0.08 | |||
| Yes | 9 (23.7%) | 22 (42.3%) | 21 (41.2%) | |||
| No/unknown | 29 (76.3%) | 30 (57.7%) | 30 (58.8%) | |||
| Radiation | Ref | 0.21 | 0.91 | |||
| Yes | 4 (10.5%) | 2 (3.8%) | 5 (9.8%) | |||
| No/unknown | 34 (89.5%) | 50 (96.2%) | 46 (90.2%) |
Ref, reference.